A simple blood test may reveal kidney damage in lupus — no biopsy needed?

NCT ID NCT07763834

Not yet recruiting Diagnosis Sponsor: Assiut University Source: ClinicalTrials.gov ↗

First seen Aug 13, 2026 · Last updated Aug 14, 2026 · Updated 1 time

Summary

This study asks whether levels of uromodulin, a protein in the blood, can indicate the severity of kidney damage in people with lupus nephritis. Researchers will compare uromodulin levels with kidney biopsy results from 90 participants, including those with different classes of lupus nephritis and active lupus without kidney involvement. If uromodulin correlates with biopsy findings, it could become a less invasive way to monitor the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Uromodulin (a protein measured in blood as a potential biomarker)
What this could lead to: If uromodulin levels match biopsy results, it could offer a less invasive way to monitor kidney damage in lupus nephritis, potentially reducing the need for repeated biopsies.
What could go wrong: This is an early, observational study with a small number of participants. Uromodulin may not reliably reflect biopsy findings, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLOMERULONEPHRITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glomerulonephritis lupus nephritis systemic lupus erythematosus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SLE UROMODULIN

More trials for these conditions

Other studies related to the condition(s) this trial covers.